Nicotinic acid metabolite blood sample preservation and detection method, kit and application thereof
By adding trichloroacetic acid to blood samples and preserving it at low temperature, the problems of extracellular instability and mutual conversion of niacin metabolites were solved, and the stability and accurate detection of NAD+, NMN, and NAM were achieved, and clinical samples were simplified. processing and detection process.
Patent Information
- Application Number
- CN202410066739.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-10-24
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to accurately detect niacin metabolites such as NAD+, NMN, NAM outside the cell, and these substances are unstable in blood samples and are easily transformed into each other, affecting the accuracy of the detection results, especially during the collection, transportation and storage process. middle.
Add trichloroacetic acid (TCA) to whole blood and red blood cell samples and store it at low temperature at 0-6°C to prevent the mutual conversion of NAD+, NMN and NAM and ensure their stability. The analysis was performed using high-performance liquid chromatography tandem mass spectrometry detection method. .
Through the addition of TCA and low temperature storage, the stability of NAD+, NMN and NAM is significantly improved, the sample collection, transportation and detection process is simplified, the accuracy and sensitivity of the detection results are ensured, the cost is reduced, and it is suitable for clinical applications.
Smart Images

Figure CN118901699A_ABST
Abstract
Description
[0001] This application is a divisional application of parent case 202311377739X, with application date October 24, 2023. Technical Field
[0002] The present invention belongs to the technical field of biochemical analysis, and in particular, relates to a method for preserving and detecting a niacin metabolite blood sample, a kit and application thereof. Background Art
[0003] Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme present in all living cells. It is known that the physiological activities of more than 300 enzymes depend on NAD+. NAD+ is the energy source for hundreds of biological metabolic processes in the human body. It is involved in maintaining mitochondrial function, DNA repair, activating longevity proteins, providing energy to cells, and removing genes that accelerate the aging process. A decrease in NAD+ levels can be found in almost all age-related diseases (including neurodegenerative diseases, diabetes, and cancer), and the progression of related diseases can be slowed by increasing NAD+ levels. In addition, studies have found that disorders in NAD+ synthesis can also lead to NAD+ deficiency and congenital malformations in humans and mice. Supplementing niacin during pregnancy can prevent malformations in mice. Therefore, NAD+ is a key substance in the human body and has an irreplaceable role in the body. Its level in the body is closely related to the aging process, birth defects, etc.
[0004] NAD+ is mainly synthesized through three pathways, namely the de novo synthesis pathway, the Preiss-Handler pathway, and the salvage pathway. Among them, nicotinamide (NAM), nicotinamide mononucleotide (NMN), and tryptophan (TRP) are the main precursors for the synthesis of NAD+, among which NAD+, NAM, and NMN are constantly converted in cells. The main metabolites kynurenine (KYN) and quinolinic acid (QA) in the de novo synthesis pathway have been reported to be associated with a variety of diseases. The expression level of KYN is largely related to the clinical characteristics and adverse clinical outcomes of various diseases, while QA can produce neurotoxic effects and participate in the pathophysiological processes of neuropsychiatric diseases such as Alzheimer's disease, Parkinson's disease, and depression.
[0005] The anti-aging function of NAD+ has been continuously confirmed, but due to the unstable nature of NAD+ outside the cell, NAD+ and NMN, NAM are easily converted into each other, making it difficult to accurately detect substances such as NAD+. In particular, for clinical samples, whether collected by the hospital or collected by individuals, it usually takes a period of time from sample collection to detection, which seriously affects the accuracy of the test results. However, there are few studies on the stability of NAD+ / NMN / NAM in the current literature and patents. The existing method is to process or freeze the sample immediately after collection (Matsuyama R, Omata T, Kageyama M, et al. Stabilization and quantitative measurement of nicotinamide adeninedinucleotide in human whole blood using dried blood spot sampling [J]. Analytical and Bioanalytical Chemistry, 2023, 415 (5): 775-785.), but the operation of immediate freezing is not only not conducive to the collection of clinical samples, but also increases the cost of freezing and transportation, and it is still difficult to guarantee whether the sample can be accurately detected after freezing and thawing once.
[0006] CN115372327A provides a method for detecting intracellular NMN, using NMN conversion solution to convert all NMN in cell lysate into NAD+, and then coupling the alcohol dehydrogenase cycle reaction, wherein trichloroacetic acid is used as acid extraction solution, Tris solution is used as neutralization solution, sodium phosphate buffer is used as lysis solution, etc. However, this method can only detect NMN, and cannot detect NAD+, NMN, NAM and other substances at the same time, and does not mention how to solve the problem of easy mutual conversion between NAD+ and NMN, NAM in the sample.
[0007] Therefore, it is necessary to develop new technologies to simplify, accurately and reproducibly monitor the dynamic NAD+ and various niacin metabolites in patients and healthy people, and to keep the NAD+, NMN and NAM contents in the samples stable and prevent them from converting into each other. Summary of the invention
[0008] To solve the above problems, the present invention provides a method for preserving and detecting blood samples for detecting niacin metabolites. It is found that TCA can not only improve the stability of NAD+, NMN, and NAM in whole blood and / or red blood cell samples, but also precipitate proteins and remove impurities. By adding TCA to whole blood and red blood cell samples and storing them at 4°C, they can be stably preserved for 3 months. After the samples are taken out and centrifuged, they can be loaded for high performance liquid chromatography tandem mass spectrometry detection. The operation process is very simple and can ensure the accuracy and sensitivity of the test results, which greatly facilitates the collection, transportation, preservation and detection of clinical samples.
[0009] The present invention has found through preliminary experimental results that NAD+, NMN, and NAM are very unstable in whole blood and red blood cell samples and are easily converted to each other. As the blood sample is stored for a longer time, the NAM concentration in the sample will increase, while the NMN concentration will decrease. Moreover, after freezing and thawing once, the NAM concentration will increase significantly, and NAD+ will be significantly degraded, which seriously affects the detection accuracy of NAD+ related metabolites. Therefore, the purpose of the present invention is to realize a technology that can reduce the mutual conversion of NAD+ / NMN / NAM in cells, so that the concentrations of NAD+, NAM and NMN are stable over a period of time, so as to facilitate the collection, transportation, storage and detection of clinical patient samples.
[0010] In the actual clinical testing process, due to the large sample size, it is difficult to complete the test in a short time. Usually, the collected samples need to be stored for a period of time before they can be tested. At this time, because NAD+, NMN, and NAM are very unstable in whole blood and red blood cell samples and are easily converted into each other, it is difficult to obtain accurate test results. The existing method usually uses -80℃ freezing, but -80℃ freezing is not only costly and cumbersome, but each freeze-thaw also affects the stability of NAD+, NMN, and NAM, making it difficult to ensure the accuracy of the test results.
[0011] The present invention finds that this problem can be solved perfectly by simply adding trichloroacetic acid (TCA) to the sample, without the need to freeze it at -80°C. Instead, it can be refrigerated at 0 to 6°C. This not only simplifies the operation process, eliminates the need for freeze-thaw and reduces costs, but also ensures the stability of NAD+, NMN, and NAM, thereby obtaining more accurate test results.
[0012] NAD+ in the human body is mainly present in the outer membrane, endoplasmic reticulum and endoplasmic reticulum cavity of mitochondria, so it is mainly in cells. The plasma after separating red blood cells does not contain NAD+. But at the same time, NAD+, NMN and NAM are very unstable, which is the result of the mutual conversion of NAD+ / NMN / NAM ( Figure 1 ), which may be related to the enzymes in the cells or the redox environment or pH of the solution. NAD+, NMN, and NAM in whole blood samples and red blood cell samples are all unstable.
[0013] The present invention has found through extensive research that adding a precipitant TCA to a whole blood sample or a red blood cell sample helps to improve the stability of NAD+, NMN, and NAM, and reduce the intracellular conversion of NAD+ / NMN / NAM. The reason may be that the acidic TCA precipitant hinders the conversion between NAD+ / NMN / NAM, but not all acidic precipitants can improve the stability of NAD+, NMN, and NAM. Among the selected acidic precipitants, TCA has a significant and outstanding effect in this regard.
[0014] Compared with whole blood samples, TCA has a more prominent effect on the stability of NAD+, NMN, and NAM in red blood cell samples.
[0015] The preparation process of the red blood cell sample of the present invention is as follows: the whole blood sample is centrifuged, the supernatant (plasma) is removed, and the remaining part is repeatedly washed with physiological saline to obtain a red blood cell sample (RBC sample).
[0016] In one aspect, the present invention provides a method for preserving a blood sample for detecting niacin metabolites, the method comprising the following steps:
[0017] (1) Centrifuging a whole blood sample to prepare a red blood cell sample;
[0018] (2) adding TCA to the red blood cell sample, mixing, and storing at a low temperature to obtain a stored sample; the TCA is a 5% to 15% TCA solution; the low temperature is 0 to 6° C., and the storage period is no more than 3 months;
[0019] The niacin metabolites include NAD+, TRP, KYN, QA, NMN, and NAM.
[0020] In some methods, the red blood cell sample needs to be stored at a low temperature of 0 to 6°C. Cryogenic storage can help further improve the effect of TCA on inhibiting the mutual conversion of NAD+, NMN, and NAM. If only TCA is added without low-temperature storage at 0 to 6°C, there may still be some problems with the mutual conversion of NAD+, NMN, and NAM, so cryogenic storage is preferred. When the cryogenic storage is below 0°C, the sample detection needs to undergo a freeze-thaw process, which brings inconvenience to transportation, storage, and detection, and increases costs; storage at room temperature will also affect the stability of NAD+, NMN, and NAM in the blood sample due to the high temperature, affecting the accuracy of the detection. The preferred cryogenic storage temperature must be 0 to 6°C.
[0021] Furthermore, the TCA is a 10% TCA solution; the volume ratio of the red blood cell sample to the 10% TCA solution is 1:2.
[0022] The concentration of TCA solution will not only affect the stability of NAD+, NMN, and NAM, but also the detection sensitivity of NAD+, TRP, KYN, QA, NMN, and NAM. It is necessary to find the optimal concentration that can ensure the stability of NAD+, NMN, and NAM and improve the detection sensitivity of NAD+, TRP, KYN, QA, NMN, and NAM. A large number of screening experiments have shown that 10% TCA solution has the best effect.
[0023] Furthermore, the low temperature is 4°C.
[0024] The most preferred cryopreservation temperature is 4°C.
[0025] The preserved samples prepared by the preservation method provided by the present invention can be stably preserved for 3 months, and the contents of NAD+, TRP, KYN, QA, NMN, and NAM therein are not significantly different from those in the initial state.
[0026] On the other hand, the present invention provides a method for detecting niacin metabolites in a blood sample by high performance liquid chromatography tandem mass spectrometry, wherein the method uses a preserved sample prepared by the preservation method described above, centrifuges the supernatant, and performs high performance liquid chromatography tandem mass spectrometry detection.
[0027] The stored samples can be used anytime within the 3-month storage period. After taking out the stored samples, you only need to centrifuge to get the supernatant and then perform the sample test, which is very convenient and efficient.
[0028] In the present invention, if a solution containing TCA is added to the blood sample, the supernatant is first centrifuged and then stored at low temperature, the steps for clinical sample collectors are more complicated. A better operation method is: after the solution containing TCA is added to the blood sample, it is directly stored and transported at low temperature, and the samples required for detection are concentrated in the detection laboratory and centrifuged before being uniformly loaded and tested. Such operation is more conducive to the collection of clinical samples.
[0029] In another aspect, the present invention provides a kit for detecting niacin metabolites in a blood sample by high performance liquid chromatography tandem mass spectrometry, the kit comprising a sample pretreatment reagent, the pretreatment reagent being a 10% TCA solution; the detection of niacin metabolites comprises the detection of NAD+, TRP, KYN, QA, NMN, and NAM; and the blood sample is a red blood cell sample.
[0030] Furthermore, the kit also includes a standard and a liquid chromatography mobile phase; the standard sample is a sample containing standard concentrations of NAD+, TRP, KYN, QA, NMN, and NAM; the liquid chromatography mobile phase includes mobile phase A and mobile phase B, mobile phase A is a 0.1% formic acid aqueous solution, and mobile phase B is a 0.1% formic acid methanol solution.
[0031] On the other hand, the present invention provides the use of TCA for preparing a reagent for improving the stability of NAD+, NMN, and NAM in a blood sample, wherein the blood sample is a red blood cell sample, the TCA is a 5% to 15% TCA solution, and the red blood cell sample needs to be stored at a low temperature after being treated with TCA, the low temperature is 0 to 6°C, and the storage period does not exceed 3 months.
[0032] Furthermore, the red blood cell sample needs to be stored at a low temperature, and the low temperature is 4° C.; the TCA is a 10% TCA solution.
[0033] In another aspect, the present invention provides a use of TCA for preparing a pretreatment reagent for a blood sample to be tested for niacin metabolites, wherein the pretreatment reagent is a reagent that can inhibit the mutual conversion of NAD+, NMN, and NAM in the blood sample and remove protein impurities in the blood sample, wherein the blood sample is a red blood cell sample, and the TCA is a 5% to 15% TCA solution. After being treated with TCA, the red blood cell sample needs to be stored at a low temperature of 0 to 6°C, and the storage period does not exceed 3 months.
[0034] Adding TCA to red blood cell samples can not only improve the stability of NAD+, NMN, and NAM in blood samples, but also precipitate proteins, thereby removing impurities in the samples and achieving a purification effect.
[0035] Furthermore, the red blood cell sample needs to be stored at a low temperature, and the low temperature is 4° C.; the TCA is a 10% TCA solution.
[0036] In some embodiments, the present invention provides the use of TCA for preparing a reagent for improving the stability of NAD+, NMN, and NAM in a blood sample, wherein the blood sample includes a whole blood sample and / or a red blood cell sample.
[0037] TCA has the effect of improving the stability of NAD+, NMN, and NAM for both whole blood samples and red blood cell samples, among which the effect of improving the inhibition of the mutual conversion of NAD+, NMN, and NAM is more prominent in red blood cell samples. That is to say, compared with adding TCA to whole blood samples, adding TCA to red blood cell samples has a more obvious effect on improving the stability of NAD+, NMN, and NAM. Therefore, the blood sample is preferably a red blood cell sample. However, it is understandable that TCA has corresponding effects on whole blood samples and / or red blood cell samples.
[0038] In some embodiments, the present invention provides the use of TCA for preparing a pretreatment reagent for a blood sample to be tested for niacin metabolites, wherein the pretreatment reagent is a reagent that can inhibit the mutual conversion of NAD+, NMN, and NAM in the blood sample and remove impurities in the blood sample, and the blood sample includes a whole blood sample and / or a red blood cell sample.
[0039] In some embodiments, the present invention provides a method for preserving a blood sample for detecting niacin metabolites, the method comprising: adding a solution containing TCA to a whole blood sample, mixing, and preserving the sample at a low temperature to obtain a preserved sample; the low temperature is 0 to 6° C., and the shelf life does not exceed 3 months.
[0040] In some embodiments, the present invention provides a combination of TCA and a cryogenic storage method for improving the stability of NAD+, NMN, and NAM in a blood sample, wherein the blood sample includes a whole blood sample or a red blood cell sample, the TCA is a 10% TCA solution, and the cryogenic storage method is a cryogenic storage at 4°C, and the shelf life does not exceed 3 months.
[0041] The present invention has the following beneficial effects:
[0042] (1) It was found that adding TCA to blood samples can help improve the stability of NAD+, NMN, and NAM and reduce the intracellular conversion of NAD+ / NMN / NAM;
[0043] (2) TCA can not only inhibit the mutual conversion of NAD+, NMN, and NAM in blood samples, but also act as a precipitant to remove impurities in blood samples, which is beneficial to the accurate detection of NAD+, NMN, NAM, TRP, KYN, and QA. The pretreatment can be completed in one step.
[0044] (3) TCA is added to the blood sample and stored at low temperature. It can be stably stored for 3 months. After the sample is taken out and centrifuged, it can be loaded for high-performance liquid chromatography-tandem mass spectrometry detection. The operation process is very simple, the detection time is only 4 minutes, and the accuracy and sensitivity of the test results can be guaranteed. It greatly facilitates the collection, transportation, storage and detection of clinical samples and is more suitable for clinical applications. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 This is a diagram of the mutual conversion relationship between NAD+, NMN, and NAM;
[0046] Figure 2 is a chromatogram of niacin metabolites in Example 1;
[0047] Figure 3 is the standard curve of nicotinamide adenine dinucleotide in Example 1 of the present invention;
[0048] Figure 4 is the standard curve of nicotinamide in Example 1 of the present invention;
[0049] Figure 5 is the standard curve of nicotinamide mononucleotide in Example 1 of the present invention;
[0050] Figure 6 is the standard curve of tryptophan in Example 1 of the present invention;
[0051] Figure 7 is the standard curve of kynurenine in Example 1 of the present invention;
[0052] Figure 8 is the standard curve of quinolinic acid in Example 1 of the present invention; DETAILED DESCRIPTION
[0053] The present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be pointed out that the embodiments described below are intended to facilitate the understanding of the present invention and do not have any limiting effect on the present invention.
[0054] Example 1 Sample preparation, pretreatment and detection
[0055] 1. Sample preparation
[0056] 1. Preparation of standard products
[0057] Prepare NAD+, TRP, KYN, QA, NMN, and NAM standards into a mixed solution as the standard working solution using deionized water to prepare the standard curve samples.
[0058] NAD+, TRP, KYN, QA, NMN, and NAM have 8 concentration series (S1 to S8) in the standard products, as shown in Table 1:
[0059] Table 1. 8 series of concentrations of standard products (S1 to S8)
[0060] ng / ml NAD+ TRP KYN QA NMN NAM S1 390.63 156.25 7.81 7.81 7.81 7.81 S2 781.25 312.50 15.63 15.63 15.63 15.63 S3 1562.50 625 31.25 31.25 31.25 31.25 S4 3125 1250 62.50 62.50 62.50 62.50 S5 6250 2500 125 125 125 125 S6 12500 5000 250 250 250 250 S7 25000 10000 500 500 500 500 S8 50000 20000 1000 1000 1000 1000
[0061] 2. Preparation of internal standard solution
[0062] The internal standards of NAD+, TRP, KYN, QA, NMN, and NAM are NAD-d4, TRP-d5, KYN-d4, QA-13C3,15N, NMN-d4, and NAM-d4, respectively, which are prepared with deionized water to prepare internal standard solutions with concentrations of 1000, 1000, 100, 100, 100, and 100 ng / mL, respectively.
[0063] 2. Sample Pretreatment
[0064] (1) A 2 mL whole blood sample was obtained clinically and immediately centrifuged (centrifugation conditions: 1000 g, 5 min). The supernatant was removed and the remaining precipitate was washed with 2 volumes of physiological saline to obtain approximately 2 mL of red blood cell sample (RBC sample).
[0065] (2) Take 100 μL of whole blood or red blood cell sample, add 200 μL of 10% TCA solution and 100 μL of internal standard solution, vortex mix for 1 min, and store at 4°C until testing. The storage period shall not exceed 3 months.
[0066] 3. Sample Testing
[0067] The supernatant was detected by high performance liquid chromatography tandem mass spectrometry. The specific analysis conditions were as follows:
[0068] Liquid chromatography conditions: The liquid chromatography uses a chromatographic column Force C18, 3μm, 100*3mm; chromatographic column temperature: 40°C; flow rate: 0.6mL / min; the mobile phase includes: A: water containing 0.1% formic acid, B: methanol containing 0.1% formic acid, and the gradient elution conditions are: 0-2 minutes, 2-90% B; 2-2.9 minutes, 90% B; 2.9-3 minutes, 90-2% B; 3-4 minutes, 2% B.
[0069] Mass spectrometry conditions:
[0070] Ion Mode ESI Curtain Gas 35 IonSpray Voltage 5500 Temperature 550 lon Source Gas1 55 lon Source Gas2 55 Collision Gas 7 Scan type MRM
[0071] The ion pair information is as follows:
[0072]
[0073]
[0074] The six analytes, NAD+, TRP, KYN, QA, NMN, and NAM, can be quantitatively analyzed by detecting the peak areas of the chromatographic peaks of the above substances and internal standard ion pairs, as well as the retention times corresponding to the chromatographic peaks. The chromatograms of each metabolite are detailed in the attached Figure 2 , standard curve see Figure 3-Figure 8 .
[0075] Example 2 Comparison of the effects of adding TCA to different samples
[0076] This example uses clinical samples, and the samples to be tested are prepared according to the method provided in Example 1, wherein the samples are processed as follows: 1. The whole blood sample is centrifuged, the supernatant is removed, and the sample is resuspended in physiological saline to prepare an RBC sample, and then a 10% TCA solution is added; 2. A 10% TCA solution is directly added to the whole blood sample; 3. The whole blood sample is centrifuged, the supernatant is taken to prepare a plasma sample, and then a 10% TCA solution is added. According to the method provided in Example 1, 6 kinds of test objects are tested, and the contents of the initial state and after 10 days of low temperature storage at 4°C are tested respectively, and RBC samples and whole blood samples without adding 10% TCA are used as blank controls (no TCA is added first, and TCA is added for pretreatment before the sample is tested). The results are shown in Table 1 (initial state) and Table 2 (10 days of low temperature storage at 4°C).
[0077] Table 1. Comparison of the effects of adding TCA to different samples (initial state)
[0078]
[0079]
[0080] ND: Not Detected
[0081] Table 2. Comparison of the effects of adding TCA to different samples (stored at 4°C for 10 days)
[0082]
[0083] ND: Not Detected
[0084] The data in Table 1 and Table 2 provided in this example need to be compared to compare the NAD+, NMN, and NAM contents of each group in the initial state and the NAD+, NMN, and NAM contents after 10 days of low-temperature storage at 4°C, with a focus on examining whether the NAD+, NMN, and NAM contents after 10 days of storage have converted into each other relative to the initial state.
[0085] According to Tables 1 and 2, it can be seen that in the initial state, the NAD+ content in the whole blood sample and the RBC sample is relatively close, because NAD+ only exists in cells, NMN and NAM are distributed in different proportions in the RBC sample and the whole blood sample, and the content of NAD+, NMN and NAM in the plasma sample is very low.
[0086] By comparing groups 1 and 2 and the blank control, after 10 days of storage at 4°C, the concentrations of NAD+ and NMN in the blank control without TCA in the whole blood and red blood cell samples decreased significantly, while the concentration of NAM increased significantly, indicating that NAD+, NMN, and NAM are very unstable in the whole blood and RBC samples. After adding TCA, the concentrations of NAD+, NMN, and NAM in the whole blood and RBC samples remained almost unchanged, which shows that adding TCA to whole blood or RBC samples can help improve the stability of NAD+, NMN, and NAM and prevent mutual conversion.
[0087] At the same time, it can also be seen that compared with whole blood samples, the added TCA in RBC samples has better stability and can more effectively inhibit the mutual conversion of NAD+, NMN and NAM. There is almost no obvious change before and after low-temperature storage.
[0088] Example 3 Effects of different precipitants on the detection and stability of niacin metabolites
[0089] 1. Screening of precipitants
[0090] In order to find a precipitant with better recovery rate for the six analytes NAD+, TRP, KYN, QA, NMN, and NAM, this example compared different precipitants as described in Table 3. While selecting a precipitant with better recovery rate, it was found that TCA was not only the precipitant with the highest recovery rate, but also had the best effect in improving the stability of NAD+, NMN, and NAM.
[0091] This example uses clinical samples, and performs sample pretreatment and storage according to the method provided in Example 1, wherein the added TCA solution is replaced with a variety of precipitants as shown in Table 3, and after the sample is pretreated, it is stored at 4°C for 10 days, 1 month, and 3 months. According to the method provided in Example 1, 6 analytes are tested, and RBC samples without adding 10% TCA are used as blank controls. The results are shown in Table 3 (initial state), Table 4 (4°C low temperature storage for 10 days), Table 5 (4°C low temperature storage for 1 month), and Table 6 (4°C low temperature storage for 3 months).
[0092] Table 3. Selection of precipitant (initial state)
[0093]
[0094] Table 4. Selection of precipitants (stored at 4°C for 10 days)
[0095]
[0096] Table 5. Selection of precipitants (stored at 4°C for 1 month)
[0097]
[0098] Table 6. Selection of precipitants (stored at 4°C for 3 months)
[0099]
[0100]
[0101] The data in Tables 4 to 6 provided in this example need to be compared to compare the NAD+, NMN, and NAM contents of each group in the initial state, as well as the NAD+, NMN, and NAM contents after 10 days and 3 months of low-temperature storage at 4°C, with a focus on examining whether the NAD+, NMN, and NAM contents after 10 days and 3 months of storage have converted to each other relative to the initial state.
[0102] It can be seen from Table 3 that the recovery rates of NAD+ and other substances using different precipitants are completely different. The recovery rates of hydrochloric acid, trichloroacetic acid and sulfosalicylic acid are higher, among which 10% TCA has the highest recovery rate, while the recovery rates of commonly used precipitants such as ethanol, acetonitrile, methanol, etc. are very low.
[0103] From Tables 3 to 5, it can be seen that the use of acidic precipitants helps to improve the stability of NAD+, NMN, and NAM, but the effects of hydrochloric acid and sulfosalicylic acid are not ideal. TCA has an unparalleled effect on improving the stability of NAD+, NMN, and NAM. The reason may be that TCA can effectively inhibit enzyme activity and lipid oxidation, while also quickly precipitating proteins and stabilizing the substances to be tested.
[0104] It can be seen that TCA is the most preferred precipitant, which can not only improve the stability of NAD+, NMN, and NAM in blood samples, but also remove impurities in blood samples and improve the recovery rate of substances such as NAD+ in red blood cell samples.
[0105] In addition, from Tables 3 to 6, it can be seen that when TCA is added and stored at 4°C for one month, the content of substances such as NAD+ can maintain very good stability. However, after 3 months, the content of NAM shows an upward trend, affecting the accuracy of the test. Therefore, the recommended storage period for the sample is within 3 months.
[0106] Example 4 Screening of TCA concentration
[0107] In this example, clinical samples were used, and the samples were pre-treated and stored according to the method provided in Example 1. The added concentrations of TCA solution were respectively as shown in Table 7. The effect of the concentration of TCA solution added to 100 μL of red blood cell sample on the recovery rate of the analytes and the stability of NAD+, NMN, and NAM was investigated. Six analytes were detected according to the method provided in Example 1 (since TRP, KYN, and QA are relatively stable, only the detection results of NAD+, NMN, and NAM are listed in Table 7). The contents in the initial state and after 10 days of low-temperature storage at 4°C were detected, and the results are shown in Table 7.
[0108] Table 7. Screening of TCA Dosage Concentration
[0109]
[0110]
[0111] From Table 7, it can be seen from the comparison of the NAD+, NMN, and NAM contents of each group in the initial state and after 10 days of low-temperature storage at 4°C that a too high TCA solution concentration (such as 15%) will reduce the recovery rate of NAD+ and NMN analytes and the accuracy of the test results, making the NAD+, NMN, and NAM contents obtained in the initial state detection low); while a too low TCA solution concentration (such as 5%) will affect the stability of NAM. After 10 days of storage at 4°C, the NAM content increases significantly, and the efficacy of inhibiting the mutual conversion of NAD+, NMN, and NAM decreases. Therefore, for a 100μL red blood cell sample, the most preferred TCA solution addition concentration is 10%.
[0112] Example 5 Effect of Storage Temperature
[0113] In this example, clinical samples were used, and the samples were pre-treated and stored according to the method provided in Example 1. After adding 200 μL of 10% TCA solution, the samples were stored at different temperatures as shown in Table 8 to investigate the effect of the storage temperature of the RBC samples on the stability of NAD+, NMN, and NAM. NAD+, NMN, and NAM were detected according to the method provided in Example 1, and the contents in the initial state and after 10 days of storage were detected. The results are shown in Table 8.
[0114] Table 8. Impact of preservation
[0115]
[0116] According to Table 8, by comparing the NAD+, NMN, and NAM contents of each group in the initial state and after 10 days of low-temperature storage at 4°C, it can be seen that low-temperature storage is also a very important condition to ensure the stability of NAD+, NMN, and NAM and inhibit mutual conversion. Once the storage temperature reaches above 6°C, especially above 15°C, the stability of NAD+, NMN, and NAM decreases rapidly and cannot be preserved, seriously affecting the accuracy of the test results. Therefore, after adding 10% TCA solution to the red blood cell sample, the preferred storage temperature is 0-6°C, and the optimal storage temperature is 4°C.
[0117] Example 6 Clinical validation experiment
[0118] Clinical samples were taken, and internal standards corresponding to the target objects to be tested were added according to Table 10. The samples were tested according to the method provided in Example 1. Six samples were tested in parallel after pretreatment, and the spiked recovery rate was calculated. The spiked recovery rates were tested in the initial state and after 2 months of low-temperature storage at 4°C. The results are shown in Tables 9 to 12.
[0119] Table 9. Clinical validation test results (before spiking, initial state)
[0120]
[0121] Table 10. Clinical validation test results (after spike, initial state)
[0122]
[0123] Table 11. Clinical validation test results (pre-spiking, stored at 4°C for 2 months)
[0124]
[0125] Table 12. Clinical validation test results (after spike, stored at 4°C for 2 months)
[0126]
[0127] Based on the above data, we investigated the precision and recovery of 6 target analytes. Regardless of the initial state or after 2 months of low-temperature storage at 4°C, the spiked recovery rate of this method was basically between 95% and 105%, with high detection accuracy, indicating that this method meets clinical detection requirements.
[0128] Although the present invention is disclosed as above, the present invention is not limited thereto. Any person skilled in the art can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the scope defined by the claims.
Claims
1. A method for preserving a blood sample for detecting niacin metabolites, characterized in that: The method comprises: directly adding 10% TCA solution to a whole blood sample and storing the sample at a low temperature; Or it can be composed of the following steps: (1) Centrifuging a whole blood sample to prepare a red blood cell sample; (2) adding TCA to the red blood cell sample, mixing, and storing at a low temperature to obtain a stored sample; the TCA is a 5% to 15% TCA solution; the low temperature is 0 to 6° C., and the storage period is no more than 3 months; The niacin metabolites include NAD+, TRP, KYN, QA, NMN, and NAM.
2. The storage method according to claim 1, characterized in that The TCA is a 10% TCA solution; the volume ratio of the red blood cell sample or the whole blood sample to the 10% TCA solution is 1:
2.
3. The storage method according to claim 2, characterized in that: The low temperature is 4°C.
4. A method for detecting niacin metabolites in a blood sample by high performance liquid chromatography tandem mass spectrometry, characterized in that: The preserved sample prepared by the preservation method according to any one of claims 1 to 3 is centrifuged to obtain the supernatant, which is then subjected to high performance liquid chromatography tandem mass spectrometry detection.
5. A kit for detecting niacin metabolites in blood samples by high performance liquid chromatography tandem mass spectrometry, characterized in that: The method comprises a sample pretreatment reagent, wherein the pretreatment reagent is a 10% TCA solution; the niacin metabolites include NAD+, TRP, KYN, QA, NMN, and NAM; and the blood sample is a red blood cell sample or a whole blood sample.
6. The kit according to claim 5, characterized in that It also includes a standard sample and a liquid chromatography mobile phase; the standard sample is a sample containing standard concentrations of NAD+, TRP, KYN, QA, NMN, and NAM; the liquid chromatography mobile phase includes mobile phase A and mobile phase B, mobile phase A is 0.1% formic acid aqueous solution, and mobile phase B is 0.1% Formic acid in methanol.
7. The use of TCA for preparing a reagent for improving the stability of NAD+, NMN, and NAM in a blood sample, characterized in that: The blood sample is a red blood cell sample or a whole blood sample, the TCA is a 5% to 15% TCA solution, and the red blood cell sample or the whole blood sample needs to be stored at a low temperature after being treated with TCA, the low temperature is 0 to 6° C., and the storage period does not exceed 3 months.
8. The use according to claim 7, characterized in that The low temperature is 4° C.; the TCA is a 10% TCA solution.
9. The use of TCA as a pretreatment reagent for preparing a blood sample to be tested for niacin metabolites, characterized in that: The pretreatment reagent is a reagent that can inhibit the mutual conversion of NAD+, NMN, and NAM in the blood sample and remove protein impurities in the blood sample. The blood sample is a red blood cell sample or a whole blood sample. The TCA is a 5% to 15% TCA solution. The red blood cell sample or the whole blood sample needs to be stored at a low temperature after TCA treatment. The low temperature is 0 to 6°C, and the storage period does not exceed 3 months.
10. The use according to claim 9, characterized in that The low temperature is 4° C.; the TCA is a 10% TCA solution.
Citation Information
Cited By
Method for detecting NAD < + > in multiple samples
CN119985824A
